On August 18th, 1992, Changchun Changsheng Biotechnology Co., Ltd. (formerly Changsheng Industry) was established, becoming the first joint-stock pilot enterprise in Changchun.

In p>1993, the company began to produce live attenuated hepatitis A vaccine, which became the first flagship product.

In p>1994, rabies vaccine workshop and hepatitis A vaccine workshop were put into production;

On November 18th, 1994, Changsheng Building was completed, and the company officially settled in the Development Zone, and the external image of Changsheng began to be established.

In p>1995, rabies vaccine was produced and the vaccine production workshop was expanded;

In p>1997, the trademark of "Wan Xin" was officially registered, and Changsheng had its own brand.

In p>1997, we invested in building a workshop for hepatitis A vaccine production to expand the production scale;

in p>1999, the inactivated influenza vaccine was developed;

In p>2, the rabies vaccine for human use (Vero cells) was first put on the market in China.

on October 16th, 2, three products passed SDA GMP certification at one time;

in December, 2, it was awarded the GMP Certificate of Drugs by SDA;

In March p>21, we cooperated with Hopkins University in the United States to develop AIDS vaccine.

in March p>22, the company cooperated with Peking University to develop "therapeutic and preventive DNA vaccine for hepatitis B";

In p>22, "Production of Inactivated Influenza Vaccine by Sepharose4FF Column Chromatography" won the gold medal in Geneva International Patent Technology Achievement Expo;

On September 29th, 23, "Wan Xin human rabies vaccine (Vero cell)" was awarded as "National User Satisfaction Product" by china association for quality and National User Committee.

On December 17th, 23, "Wan Xin" was recognized as "Changchun Famous Trademark" by Changchun Municipal People's Government;

in p>23, the company began to export its products;

In p>24, the technical renovation project of rabies vaccine high-tech products; The first batch of high-tech industrialization projects for the development of high-tech industries in the old industrial base of Northeast China; Eight projects, such as influenza split vaccine "24 National Innovation Fund Project for Small and Medium-sized Sci-tech Enterprises", were approved by the state and local governments, and received financial support.

In p>25, the column chromatography purification technology of influenza vaccine was authorized by the national invention patent;

In p>25, the split vaccine project was awarded the first prize of Changchun Science and Technology Progress Award;

in January p>26, all production workshops passed the national SDA GMP certification re-inspection;

In April, 27, Changchun Changsheng Institute of Biological and Life Sciences was formally established.

In September p>29, the application for registration of influenza A (H1N1) vaccine was officially approved by the State Food and Drug Administration, and it was the first split influenza A (H1N1) vaccine approved for production in Jilin Province.